#EHA2024: Aggressive B-NHL

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to Aggressive B-NHL, here.

CONGRESS #EHA2024 | Jeremy Abramson reports 3-yr follow-up data of the TRANSFORM trial of liso-cel in pts with R/R LBCL. mFU= 33.9 mo, ORR=87%, CR=74%, 36 mo PFS=50.9%, 36 mo OS=62.8% - superior to SoC. Safety was consistent with interim and primary analyses. No grade 4/5 CRS… pic.twitter.com/4voVaYLr7o

— Lymphoma Hub (@lymphomahub) June 16, 2024

CONGRESS #EHA2024 | Jeremy Abramson reports 3-yr follow-up data of the TRANSFORM trial of liso-cel in pts with R/R LBCL. mFU= 33.9 mo, ORR=87%, CR=74%, 36 mo PFS=50.9%, 36 mo OS=62.8% - superior to SoC. Safety was consistent with interim and primary analyses. No grade 4/5 CRS… pic.twitter.com/4voVaYLr7o

— Lymphoma Hub (@lymphomahub) June 16, 2024

CONGRESS #EHA2024 | Poster | Mingci Cai at Shanghai institute of hematology reports phase 2 study of tazemetostat plus amdizalisib in pts with R/R lymphomas. N=21. Azemetostat plus amdizalisib shown promising efficacy and safety in R/R lymphoma, particularly in PTCL and DLBCL,… pic.twitter.com/rInM2KkFCb

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS | #EHA2024 | David Lavie, Hadassah Medical Center presents first data of SC administration of epcoritamab + POLA-R-CHP for the treatment of first-line DLBCL.
ORR 100%, CR 88.6%, median duration of CR not reached, Grade 3/4 TEAE 76%, neutropenia 65% (all GR 3/4), CRS… pic.twitter.com/hCHbwz6m8o

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS | #EHA2024 | Sirpa Leppä @helsinkiuni shares data on biomarker-adapted treatment in high-risk LBCL. All versus biol high-risk patients 5-year OS 89% and 88%, PFS 83% and 77%, DA-EPOCH-R regimens may improve outcomes in biol-HR patients.#lymsm pic.twitter.com/1HPxEbDLf7

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS | #EHA2024 | Marcel Nijland presents the final analysis from the HOVON 151 clinical trial of atezolizumab consolidation in high-risk DLBCL. 2-year DFS 87.9%, Grade 3/4 immune-related AEs 4.5%, infections were the most common toxicity, with nearly 50% COVID-19,… pic.twitter.com/vgQkXiy6du

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS | #EHA2024
Marie José Kersten @UvA_Amsterdam @amsterdamumc presents findings from the ongoing phase I/II ATALANTA-1 trial of GLPG5101, showing the feasibility of decentralized CAR T-cell manufacturing in 33 patients with R/R NHL, with a short vein-to-vein time and no… pic.twitter.com/ihWzxHrD0S

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS | #EHA2024
Jean Galtier @CHUBordeaux reports on 55 patients with R/R PMBCL treated with axi-cel in the French DESCAR-T registry (CARTHYM study).
▪️ Strong efficacy seen (ORR=91%, CR=80%)
▪️ At median follow-up of 23 months, estimated 2-yr PFS=68.7%; median PFS not… pic.twitter.com/A5J1B4rz24

— Lymphoma Hub (@lymphomahub) June 15, 2024